American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: http://www.sciepub.com/journal/ajidm Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
Go
American Journal of Infectious Diseases and Microbiology. 2013, 1(5), 86-91
DOI: 10.12691/ajidm-1-5-2
Open AccessArticle

KatG Gene as a Surrogate Molecular Marker Leading to Cause Drug Resistance in Mycobacterium Tuberculosis Isolates

Makeshkumar Veluchamy1, , Radha Madhavan1, Sujatha Narayanan2 and Lakshmi Rajesh2

1Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM University, Kancheepuram District, Tamilnadu, India

2Department of Immunology, National Institute for Research in Tuberculosis (NIRT) [Formerly Tuberculosis Research Centre], Indian Council of Medical Research (ICMR), Tamilnadu, India

Pub. Date: September 21, 2013

Cite this paper:
Makeshkumar Veluchamy, Radha Madhavan, Sujatha Narayanan and Lakshmi Rajesh. KatG Gene as a Surrogate Molecular Marker Leading to Cause Drug Resistance in Mycobacterium Tuberculosis Isolates. American Journal of Infectious Diseases and Microbiology. 2013; 1(5):86-91. doi: 10.12691/ajidm-1-5-2

Abstract

Multi Drug Resistant Tuberculosis (MDR-TB) is an emerging problem of great importance to public health worldwide. Resistance to Rifampicin (RIF) and Isoniazid (INH) are considered as surrogate markers for MDR-TB. Resistance in Mycobacterium tuberculosis to Rifampicin is reported to be conferred by mutation in an 81bp rifampicin resistance determining region (RRDR) of the β subunit of RNA polymerase encoded by rpoB gene corresponding to codons 507-533. Resistance to Isoniazid is conferred by mutation in Catalase-peroxidase gene (katG), alkyl hydroperoxidase gene (aphC) and enoyl acyl reductase gene (inhA). The aim of this study was to identify the mutation conferring resistance to INH and by automated DNA sequencing. Seventy-four isolates of M. tuberculosis were tested phenotypically with four anti tuberculosis drugs namely Rifmapicin (RIF), Isoniazid (INH), Ethambutol (EMB) and Streptomycin(SM) by absolute concentration method. Three isolates from pulmonary tuberculosis (PTB) patients were resistant to RIF with minimum inhibitory concentration (MIC) greater than or equal to 128µg/ml and to INH with MIC greater than are equal to 1.5 µg/ml. The genome of these three MDR-TB isolates were amplified by Polymerase Chain Reaction (PCR) and DNA sequencing was performed. All three isolates showed a point mutation at codon 315 (Ser ® Thr) in the sequenced katG region for INH resistance, but did not show any mutation in the 81bp hotspot sequenced rpoB region for resistance and promoter region of inhA and aphC for INH resistance. Two of three isolates were from patients who had not taken treatment previously which is of great concern with respect to public health.

Keywords:
Multi Drug Resistant Tuberculosisrifampicin/isoniazid PCR/DNA sequencing

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 4

References:

[1]  World Health Organization.(2005).Global tuberculosis control-surveillance, planning, financing. World Health Organization, . WHO/HTM/TB/2005.349.
 
[2]  Toungoussova O., Sandven P., Mariandyshev A., et al. (2002).Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 40, 1930-1937.
 
[3]  Wright A, Zingol M, Deun A.V et al. (2009). Epidemiology of anti-tuberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. The Lancet, 373, 1861-72.
 
[4]  World Health Organization. Anti-tuberculosis Drug Resistance in the World. Report No.4. Pre-publication version. Available from: whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.394_eng.pdf, Accessed 5 May 2008.
 
[5]  Onyebujoh P, Zumla A, Ribeiro I, et al. (2005). Treatment of tuberculosis: Present status and future prospects. Bulletin of World Health Organization 83, 857-865.
 
[6]  Mitchison DA. (1985). Mechanism of drug action in short–course chemotherapy. Bulletin International Union against Tuberculosis 65, 30-37.
 
[7]  Iseman MD, Madsen LA. (1989). Drug resistant tuberculosis. Clin Chest Med., 10, 341-5.
 
[8]  Bhatt CP, Bhatt AB, Shrestha B. (2011). Molecular characterization and comparison of multidrug resistant strains of Mycobacterium tuberculosis by phenotypic and genotypic method. SARRC J Tuber Lung Dis HIV/AIDS, VIII(2).
 
[9]  Telenti A., Imboden P., Marchesi F., et al. (1993). Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet ., 341, 647-650.
 
[10]  Yue J., Shi W., Xie J., et al. (2003). Mutation in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin Microbiol., 41, 2209-2212.
 
[11]  Bardou FC., Raynaud C., Ramos MA., et al. (1998). Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology144:2539-2544.
 
[12]  Rozwarski DA., Grant GA., Barton DHR., et al. (1998). Modification of the NADH of the isoniazid target (inhA) from Mycobacterium tuberculosis. Science., 279, 98-102.
 
[13]  Sacchettini JC, and Blanchard JS. (1996). The structure and function of the isoniazid target in Mycobacterium tuberculosis. Res Microbiol., 147, 36-43.
 
[14]  Cardoso RF., Cooksey RC., Morlock GP., et al. (2004). Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrob. Agents Chemother., 48, 3373-3381.
 
[15]  Marrakchi H, Laneelle G and Quemard A. (2000). InhA, a target of the antituberculosis drug isoniazid is involved in a mycobacterial fatty acid elongation system, Fas-II. Microbiology., 146, 289-296.
 
[16]  Mdluli K., Slayden RA., Zhu Y., et al. (1998). Inhibition of a Mycobacterium tuberculosis_-ketoacyl ACP synthase by isoniazid. Science., 280, 1607-1610.
 
[17]  Banerjee A., Dubnau E., Quemard A., et al. (1994). inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science., 263, 227-230.
 
[18]  Ducasse-Cabanot S., Cohen-Gonsaud M., Marrakchi H., et al. (2004). In vitro inhibition of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein reductase MabA by isoniazid. Antimicrob Agents Chemother., 48, 242-249.
 
[19]  Kelley CL., DA Rouse., and Morris S L., (1997). Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother., 41, 2057-2058.
 
[20]  Miesel L., Weisbrod TR., Marcinkeviciene JA., et al. (1998). NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol., 180, 2459-2467.
 
[21]  Wilson T., Lisle GW., Marcinkeviciene JA., et al. (1998). Antisense RNA to ahpC, an oxidative stress defense gene involved in isoniazid resistance, indicates that ahpC of Mycobacterium bovis has virulence properties. Microbiology., 144, 2687-2695.
 
[22]  Victor TC., Van Helden PD., (2001). Detection of mutations in Mycobacterium tuberculosis by a Dot Blot Hybridization Strategy. In: Mycobacterium tuberculosis Protocols. Methods in Molecular Medicine., New Jersey: Humana press Vol.54, 155-64.
 
[23]  Somerville W., Thibert L., Schwartzman K., et al. (2005). Extraction of Mycobacterium tuberculosis DNA: A question of containment. J Clin Microbiol., 43, 2996-7.
 
[24]  Ramasamy S., Musser JM., (1998).Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle and Lung diseases., 79, 3-29.
 
[25]  Telenti A., Imboden P., Marchesi F., et al. (1993). Direct automated detection of rifampin resistant M. tuberculosis by polymerase chain reaction and single strand conformation polymorphism analysis. Antimicrob Agents Chemother., 37, 2054-8.
 
[26]  Mani C., Selvakumar N., Sujatha N., et al. (2001). Mutations in the rpoB Gene of multi-drug resistant Mycobacterium tuberculosis Clinical isolates from India. J. Clin.Microbiol., 39, 2987-2990.
 
[27]  Mercy Aparna L., Lingala., Aparna Srikantam., et al. (2010). Clinical and geographical profiles of rpoB gene mutations in Mycobacterium tuberculosis isolates from Hyderabad and Koraput in India. Journal of Microbiology and Antimicrobials., Vol.2(2),pp.13-18.
 
[28]  Yuen Lily KW., Leslie David., Colol Peter J., (1999). Bacteriological and molecular analysis of rifampicin resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol., 37, 3844-3850.
 
[29]  Khamis N., Amin MM., Zagloul MZ., et al. (2001). DNA sequencing and bacteriophage based technique for rapid detection of rifampicin resistant Mycobacterium tuberculosis. Egypt J Med Lab Sci (ESIC)., 13(1), 28-36.
 
[30]  Heep M., Brandstatter B., Riegger U., et al. (2001), Frequency of rpoB mutation inside and outside the cluster I region in rifampin-resistant clinical M.tuberculosis isolates. J Clin Microbiol., 39, 107-10.
 
[31]  Dobner P., Rusch – Gerdes S., Bretzel G., et al. (1997). Usefulness of M.tuberculosis genomic mutation in the genes KatG and inhA for the prediction of isoniazid resistant. Int J Tubercl Lung Dis., 1, 365.
 
[32]  Heym B., Zhang Y., Poulet S., et al. (1993). Characterization of the katG gene encoding a Catalase-peroxidase required for isoniazid susceptibility of Mycobacterium tuberculosis. J. Bacteriol., 13, 4255-4259.
 
[33]  Zheltokjva EA., Chemousova LN., Smiirnova TJ., (2004). Molecular genetic typing Mycobacterium tuberculosis strains isolated from patents in the samapa region by the restriction DNA fragment length polymorphisms ZH. Microbial (Moscow), 5, 39-43.
 
[34]  Siqueria de R.H., Freitas de D.A.F., Oliveria de N.D., et al. (2009). Isoniazid resistant Mycobacterium tuberculosis strains arising from mutations in two different regions of the KatG gene. J. bras.pneumol., 35(8), 773-9.
 
[35]  Aragon L.M., Navarro F., Heiser V., et al. (2006). Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluroscent low density DNA microarrays. Journal of Antimicrobial Chemotherapy, 57, 825-83.
 
[36]  Negi S.S., Anand R., Pasha S.T., et al. (2006). Molecular characterization of mutation associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis isolates. Indian Journal of Experimental Biology., 44, 547-53.
 
[37]  Hass W.H., Schilke K., Brand J., et al. (1997). Molecular analysis of KatG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicro Agents Chemother., 1601-3.
 
[38]  Wang Y.C, Zhu R.Y, Xu Y.Y, et al. (2009). Molecular characterization of drug resistant Mycobacterium tuberculosis isolates in Guangdong, China. Jpn.J.Infect dis, 62, 270-4.
 
[39]  Hu Y., Hoffner S., Weili J., et al. (2010). Extensive transmission of isoniazid resistant M.tuberculosis and its association with increased multidrug resistant TB in two rural countries of eastern China: A molecular epidemiological study. BMC Infectious Diseases, 10(43).